Log In
Print
BCIQ
Print
Print this Print this
 

ALN-VSP, ASC-06

Also known as: formerly ALN-VSP01

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNA therapeutic targeting kinesin spindle protein (KSP) and VEGF genes
Molecular Target Vascular endothelial growth factor (VEGF) ; Kinesin spindle protein (KSP) (Eg5) (TRIP5)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationLiver cancer
Indication DetailsTreat advanced liver cancer; Treat hepatocellular carcinoma (HCC); Treat liver cancer
Regulatory Designation

Partner

Ascletis Pharmaceuticals Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

$8.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today